PHILADELPHIA, PA and VANCOUVER, British Columbia — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announce the initiation of Good Manufacturing Practice (GMP) manufacturing of its lead candidate for treating prostate cancer, Bria-Pros+. GMP manufacturing of Bria-Pros+ will provide clinical supplies for planned clinical trial use.
“Building upon the compelling pre-clinical proof-of-concept data presented at the Society for the Immunotherapy of Cancer (SITC) meeting in 2023, BriaCell’s proprietary platform technology holds significant potential to benefit patients across a spectrum of cancers. We are enthusiastic about commencing GMP manufacturing for our prostate cancer clinical candidate, continuing our efforts at transforming targeted cancer therapy via the introduction of potent personalized cellular cancer vaccines,” stated Dr. William V. Williams, BriaCell’s President and CEO. “The successful development of this first candidate showcases our capacity to create novel cancer immunotherapies and advance them towards clinical application. We eagerly anticipate completing Investigational New Drug (IND)-enabling studies during 2024 with Bria-Pros+.”
Recently presented at SITC 2023, the pre-clinical proof-of-concept data demonstrated both feasibility and efficacy of BriaCell’s platform of cellular cancer vaccines overall, with specific emphasis on Bria-Pros+. BriaCell genetically engineers cancer cell lines to produce cytokines and co-stimulatory factors that significantly increase immune stimulation compared to the unmodified (parent) cancer cell lines. These cell lines also express patient-specific Human leukocyte antigens (HLA) alleles and potentially provide personalized off the shelf treatment.
In the realm of cancer immunotherapy, the objective is to restore the body’s natural anti-tumor immunity. Despite notable progress, current approaches often fall short of achieving curative outcomes, primarily because they target specific immune processes, resulting in only partial restoration of the body’s inherent anti-cancer immunity.
An optimal cancer immunotherapy should initiate or reinstate a persistent anti-tumor immune response via both complementary and diverse mechanisms resulting in a self-sustaining cycle of cancer immunity by both the innate and adaptive immune responses. The data highlighted at the SITC meeting demonstrated that Bria-Pros+ could effectively activate the natural immune response against tumor cells by both expressing cancer antigens, and by modulating the activity of innate and adaptive immune cells. These include helper T cells (CD4+), cytotoxic (killer) T cells (CD8+), and natural killer cells (both Classical NK cells and NKT cells). Data previously presented at the SITC meeting is reproduced here in a different format.
About BriaCell Therapeutics Corp.
BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care.
Contact Information
Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
[email protected]
Media Relations:
Jules Abraham
CORE IR
[email protected]
Investor Relations Contact:
CORE IR
[email protected]